Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently
Moved to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Various biomedical topics, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial paper.
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published many of experimental research articles and theoretical articles as sole
Writer. These sole-author publications
Highlighted two crucial themes.
The first of those explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Validation their resistance. The outcomes and underlying
Concept were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the work was
Named, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
The second theme throughout Dr. Blagosklonny’s sole-author publications
Is a research method to create knowledge by
Uniting several facts together from seemingly unrelated fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Crucial result revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others cannot even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Inhibiting organism aging — in other words, “preventing cancer
Via remainng young. ” His laboratory closely worked together with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of additional anti-aging
Medicines beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging medications to be taken by humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
| 
